Unknown PHASE3 INTERVENTIONAL 2-arm NCT02070523

Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia:

Pegylated Liposomal Doxorubicin-contained Versus Daunorubicin-contained VDCLD Regimen in Previously Untreated Adult Patients With Acute Lymphoblastic Leukemia: Complete Remission Rates and Changes of Leukemia Stem Cells

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions Acute Lymphoblastic Leukemia

Interventions VDCLD regimen

Updated 5 times since 2017 Last updated: Jul 6, 2014 Started: Dec 31, 2013 Primary completion: Nov 30, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Acute Lymphoblastic Leukemia, this trial is ongoing. The trial is conducted by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. and has accumulated 5 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.

Data source: Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zhanjiang, China